SCHEMBL35064

SCHEMBL35064

[CH]1CCN2CCCC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360443 0.92
SCHEMBL9469528 0.90
SCHEMBL29264397 0.84
SCHEMBL736908 0.84 L3MBTL3 (0.32)
SCHEMBL738040 0.83
SCHEMBL206897 0.82 CYP2D6 (0.33)
SCHEMBL4159670 0.82 CYP2D6 (0.33)
SCHEMBL735435 0.82 L3MBTL3 (0.31)
SCHEMBL737602 0.82 L3MBTL3 (0.31)
SCHEMBL739062 0.82 L3MBTL3 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012404-B2 Pyrimidoheterocyclic compounds and application thereof D3 BIO (WUXI) CO., LTD. (CN) 2024-06-18 US claimed
US-20240174692-A1 PYRIMIDINE AROMATIC RING COMPOUNDS MEDSHINE DISCOVERY INC. (CN) 2024-05-30 US claimed
EP-4373827-A1 KRAS G12D INHIBITORS AND USES THEREOF Suzhou Zanrong Pharma Limited (CN) 2024-05-29 EP claimed
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 US claimed
CN-117917416-A KRAS G12D degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2024-04-23 CN claimed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 CN claimed
US-20240116934-A1 PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF D3 BIO (WUXI) CO., LTD. (CN) 2024-04-11 US claimed
EP-4349828-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Yingli Pharmaceutical Co. Ltd. (CN) 2024-04-10 EP claimed
US-20240092803-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-03-21 US claimed
CN-117645627-A Heterocyclic compound and medical application thereof 正大天晴药业集团股份有限公司 2024-03-05 CN claimed
CN-115260158-A Compound of targeted protein regulator and application thereof 上海医药集团股份有限公司 2022-11-01 CN claimed
WO-2022199587-A1 PYRIMIDINE HETEROCYCLIC COMPOUND AND APPLICATION THEREOF 南京明德新药研发有限公司 2022-09-29 WO claimed
WO-2022148421-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEIGENE, LTD. (KY) 2022-07-14 WO claimed
WO-2022148422-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEIGENE, LTD. (KY) 2022-07-14 WO claimed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 CN claimed
CN-113321654-B Fused pyridones as kinase inhibitors 上海济煜医药科技有限公司 2022-05-03 CN claimed
WO-2021259331-A1 EIGHT-MEMBERED N-CONTAINING HETEROCYCLIC COMPOUND 南京明德新药研发有限公司 2021-12-30 WO claimed
CN-113321654-A Fused pyridones as kinase inhibitors 上海济煜医药科技有限公司 2021-08-31 CN claimed
US-20100093767-A1 Mitotic Kinase Inhibitors TAKEDA SAN DIEGO, INC. (US) 2010-04-15 US claimed
WO-2006060737-A2 MITOTIC KINESIN INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-06-08 WO claimed